clinical trials, page-2

These are results from phase1. Worth considering again now that the phase2 trials are starting.
<<15 months). Of the other two significant partial responders, one patient passed away due to the long term effects of cancer (even though he had >50% tumour reduction) the other (NSCLC) is continuing to have stable disease and is experiencing GOOD QUALITY OF LIFE. It is important to note, one does not expect to see any response whatsoever in Phase I clinical studies.

“It is unusual to see radiological responses in a Phase I study. The documentation of two [such] patients in this study suggests that SBP002 does have potentially significant activity.”

Principal Investigator Professor Michael Millward,

Department of Medical Oncology

Sir Charles Gairdner Hospital

in response to the 2-hour infusion trial group>>>
IN MY OPINION THIS HAS THE POTENTIAL OF BEING THE MOST IMPORTANT PHASE 2 TRIAL AGAINST CANCER EVER CONDUCTED IN AUSTRALIA. I do not have any medical or investment advisor qualifications so please do your own DD.
Good luck to Solbec holders
http://www.solbec.com.au/general.asp?PAGE_ID=11